Anti-Glypican-1 Antibody, clone 1J4, ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 1J4 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Glypican-1. It targets an epitope within 24 amino acids from the C-terminal half.
• Immunogen: KLH-conjugated liner peptide corresponding to 24 amino acids from the C-terminal half of human Glypican-1, isoform 1.
• Application: Anti-Glypican-1, clone 1J4 ZooMAb, Cat. No. ZRB1374, a recombinant Rabbit monoclonal antibody that targets Glypican-1 and is tested in Affinity Binding, Immunofluorescence, and Immunohistochemistry, and Western Blotting.
• Target description: Glypican-1 (UniProt: P35052; also known as GPC1) is encoded y the GPC1 gene (Gene ID: 2817) in human. Glypican-1 is a cell-surface glycoprotein that attaches to the plasma membrane via via glycosylphosphatidylinositol (GPI) anchors. It is synthesized with a signal peptide (aa 1-23) and a propeptide (aa 531-538) that are subsequently cleaved off to produce mature protein. Glypican-1 undergoes N- and O-glycosylations. N-glycosylation is mainly of the complex type containing sialic acid whereas O-glycosylation is with heparan sulfate Heparan sulfate chains are cleaved either by heparinase or are degraded by deaminative process that uses nitric oxide released from the S-nitrosylated cysteines. Glypican-1 is shown to be essential for proper skeletal muscle differentiation. It can act as a catalyst in increasing the rate of conversion of prion protein PRPN(C) to PRNP(Sc) via associating with both forms of PRPN, targeting them to lipid rafts and facilitating their interaction. It can also sequester FGF2 in lipid rafts and blocks its binding to FGF receptors. Glypican-1 is specifically enriched on cancer-cell-derived exosomes and levels of glypican-1 positive exosomes correlate with tumor burden and the survival of pre- and post-surgical patients. It is also over-expressed in human gliomas and in pancreatic cancer cells. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Melo, SA et al. 2015. Nature. 523(7559):177-82; Kleeff, J., et al. 1998. J. Clin. Invest. 102(9), 1662-1673).
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.